beta
/Methods Of Treating Lipedema Including Akr1c1 As A Therapeutic Target
Abstract

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

Full Text

What is claimed is:

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.
Timeline
Filed
02/25/2026
Published
06/25/2026
Granted
Not Available
IPC Codes(43)
A61K 31/551:having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/05:Phenols
A61K 31/121:acyclic